ArticleBiomolecules & therapeutics2015
Spinosin, a C-Glucosylflavone, from Zizyphus jujuba var. spinosa Ameliorates Aβ1-42 Oligomer-Induced Memory Impairment in Mice.
Article in Biomolecules & therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- The Herbal MedicineIntegrative cancer therapiesPooled it
- Rheum undulatum Linné Exerts Neuroprotective Effects Against Aβ Oligomer-Induced Neuronal Damage by Modulating p53-Mediated Signaling.Neurochemical research · 2026Article
- Spinosin: A Critical Updated Review on Pharmacology, Pharmacokinetics, Toxicity and Translational Bottlenecks.Molecules (Basel, Switzerland) · 2026Review
- Spinosin Attenuates HCl/Ethanol-Induced Gastric Mucosal Injury by Modulating Oxidative Stress, Inflammation, Apoptosis, and Nrf2/HO-1-Associated Responses.Biomedicines · 2026Article
- Article
- A Combination of Magnoflorine and Spinosin Improves the Antidepressant effects on CUMS Mouse Model.Current drug metabolism · 2024Article
- Natural compounds regulate the PI3K/Akt/GSK3β pathway in myocardial ischemia-reperfusion injury.Cell cycle (Georgetown, Tex.) · 2023Article
- Efficacy of Kami Guibi-tang as an Add-On Therapy to Acetylcholinesterase Inhibitor for Cognitive Function in Mild Alzheimer's Disease: A Pilot Study.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Ginsenoside and Its Therapeutic Potential for Cognitive Impairment.Biomolecules · 2022Review
- Spinosin ameliorates insulin resistance by suppressing reactive oxygen species-associated inflammation.Iranian journal of basic medical sciences · 2022Article
- Medicine-Food Herbs against Alzheimer's Disease: A Review of Their Traditional Functional Features, Substance Basis, Clinical Practices and Mechanisms of Action.Molecules (Basel, Switzerland) · 2022Review
- The pharmacology, pharmacokinetics, and toxicity of spinosin: A mini review.Frontiers in pharmacology · 2022Review
- Kihito prevents corticosterone-induced brain dysfunctions in mice.Journal of traditional and complementary medicine · 2021Article
- Metagenomic and phytochemical analyses of kefir water and its subchronic toxicity study in BALB/c mice.BMC complementary medicine and therapies · 2021Article
- Effects of the fermentedNutrition research and practice · 2021Article
- Spinosin Inhibits AβBiomolecules & therapeutics · 2020Article
- Spinosin Attenuates Alzheimer's Disease-Associated Synaptic Dysfunction via Regulation of Plasmin Activity.Biomolecules & therapeutics · 2020Article
- Neuroprotective Polyphenols: A Modulatory Action on Neurotransmitter Pathways.Current neuropharmacology · 2020Review
- Spinosin and 6'''‑Feruloylspinosin protect the heart against acute myocardial ischemia and reperfusion in rats.Molecular medicine reports · 2019Article
- Methanol extract of semen Ziziphi Spinosae attenuates ethanol withdrawal anxiety by improving neuropeptide signaling in the central amygdala.BMC complementary and alternative medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder associated with progressive memory loss and neuronal cell death. Although numerous previous studies have been focused on disease progression or reverse pathological symptoms, therapeutic strategies for AD are limited. Alternatively, the identification of traditional herbal medicines or their active compounds has received much attention. The aims of the present study were to characterize the ameliorating effects of spinosin, a C-glucosylflavone isolated from Zizyphus jujuba var. spinosa, on memory impairment or the pathological changes induced through amyloid-β1-42 oligomer (AβO) in mice. Memory impairment was induced by intracerebroventricular injection of AβO (50 μM) and spinosin (5, 10, and 20 mg/kg) was administered for 7 days. In the behavioral tasks, the subchronic administration of spinosin (20 mg/kg, p.o.) significantly ameliorated AβO-induced cognitive impairment in the passive avoidance task or the Y-maze task. To identify the effects of spinosin on the pathological changes induced through AβO, immunohistochemistry and Western blot analyses were performed. Spinosin treatment also reduced the number of activated microglia and astrocytes observed after AβO injection. In addition, spinosin rescued the AβO-induced decrease in choline acetyltransferase expression levels. These results suggest that spinosin ameliorated memory impairment induced through AβO, and these effects were regulated, in part, through neuroprotective activity via the anti-inflammatory effects of spinosin. Therefore, spinosin might be a useful agent against the amyloid b protein-induced cognitive dysfunction observed in AD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.